SOFIA, Bulgaria, June 25 (SeeNews) – Israel-based Teva Pharmaceutical Industries will make a strategic investment of approximately $ 42 million to build a new drug manufacturing facility in the Bulgarian city of Dupnitsa.
The new plant will complement Teva’s existing production facility in Dupnitsa in southwestern Bulgaria, significantly increasing production capacity by over 800 million tablets / capsules per year and creating around 70 new jobs, the company said in a statement.
Production at the new plant is slated to begin at the end of 2023 after the plant has been approved by the relevant regulatory authorities.
The new production facility in Dupnitsa is part of Teva’s planned investment program for the European market over the next five years, which also includes a new global center for the production of biopharmaceuticals in Ulm, Germany, and an increase in production capacity in Zaragoza, Spain Expression. Teva currently manufactures 96% of its European drug portfolio in 15 countries across the continent, the company said.
Teva Pharmaceutical Industries owns the existing Dupnitsa facility through its local subsidiary Balkanpharma – Dupnitsa. The pharmaceutical company has a second plant in Bulgaria, which is controlled by its other local unit, Balkanpharma – Trojan.
($ = 0.835650 euros)